Long-term Antithrombotic Management of Acute Mesenteric Ischaemia: Case-based Survey
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 51
- Locations
- 1
- Primary Endpoint
- Type of antithrombotic therapy
Study Overview
Brief Summary
Guidelines on the acute and long-term pharmacological treatment of acute mesenteric ischaemia (AMI) recommend the use of thrombolytic, antiplatelet or anticoagulant therapy depending on the aetiology of AMI and the use of stenting but only few details are given on the choice of the drug, dose and duration of treatment. Besides, recommendations are mainly based on data on coronary, cerebral and other peripheral artery diseases and do also not take into account the altered drug absorption in patients with short bowel syndrome, in which AMI can result.This case-based survey will inform us on the current international clinical practice of long-term antithrombotic management of AMI.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •gastro-enterologist or cardiologist with expertise in treating SBS patients resulting from AMI
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Type of antithrombotic therapy
Time Frame: April 2023
Overview of the type of long-term antithrombotic therapy that is prescribed in SBS patients with AMI, depending on the anatomy of the gastrointestinal tract, the aetiology of AMI and whether or not revascularisation of the occluding blood vessel has been performed
Secondary Outcomes
- Dose adjustments of antithrombotic therapy(April 2023)
- Duration of antithrombotic therapy(April 2023)
- Initial dose of antithrombotic therapy(April 2023)